MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$11,506,223
Deemed dividend on
series d preferred...
$6,649,828
Net loss
-$4,856,395
Loss from operations
-$4,362,579
Total other income
(expenses), net
-$493,816
Interest income
(expense), net
$5,936
Other income
(expenses)
$248
Total operating
expenses
$4,362,579
Write off of deferred
offering costs
$500,000
Research and development
$2,386,244
General and
administrative
$1,976,335
Back
Back
Income Statement
source: myfinsight.com
CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC. (CERO)